Capital Markets Day presentations highlight opportunities and potential based on Elekta's strong position
Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments. The identified clinical need for linear accelerators (linacs) globally is around twice the number of the current installed base (14,000 linacs) and the gap is largest in emerging markets. Although these countries comprise 85 percent of the global population, they only have 40 percent of the total installed base of radiation therapy devices. Nevertheless, Elekta has a strong position in emerging markets and continues to grow, offering more patients greater hope for better outcomes.
Ensuring that equipment reaches the patient is just the beginning of the solution. Elekta's new strategy will also address improving radiation therapy technology and advanced techniques such as hypofractionation and adaptive treatments. At the same time, data, in the form of oncology informatics, will enable patients, as well as their care teams, to influence and improve their outcomes.
The Access 2025 strategy is built on four pillars: innovation, partner integration, customer focus and driving adoption of radiation therapy across the globe, reflecting Elekta's vision to create a world where everyone has access to the best cancer care. These are supported by reinforced Environmental, Social and Governance (ESG) goals.
Related to this innovation strategy, Gustaf Salford announced a strengthened partnership with Philips to develop solutions that streamline the path from cancer diagnosis to survivorship, resulting in better patient outcomes. (see press release: Elekta and Philips extend strategic partnership in precise and individualized oncology care)
CFO,
# # #
For further information, please contact:
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in
https://news.cision.com/elekta/r/elekta-s-new-strategy-to-focus-on-growth-and-access-to-radiation-therapy,c3362236
https://mb.cision.com/Main/35/3362236/1428538.pdf
(c) 2021 Cision. All rights reserved., source